Skip to Content
Merck
CN
  • Photodynamic therapy in Bowen's disease: influence of histological features and clinical characteristics on its success.

Photodynamic therapy in Bowen's disease: influence of histological features and clinical characteristics on its success.

Dermatology (Basel, Switzerland) (2014-11-18)
Annet Westers-Attema, Bjorn G P M Lohman, Fleur van den Heijkant, Patty J Nelemans, Veronique J Winnepenninckx, Nicole W J Kelleners-Smeets, Klara Mosterd
ABSTRACT

In Bowen's disease (BD) there is no consensus on optimal treatment. Photodynamic therapy (PDT) is an effective non-invasive treatment modality for BD with excellent cosmetic results. This retrospective study examines whether clinical and histological features of BD impact PDT response. Patients with previously untreated BD from 2002 until 2007 were identified at the Maastricht University Medical Centre. Patients treated with PDT were included. All histological slides were re-examined. During the study period 98 tumours were treated with PDT. In univariate analysis severe atypia and higher age were associated with decreased probability of clinical clearance. Higher age was also associated with an increased risk of recurrence. In multivariate analysis severe atypia remained the only independent risk factor for therapy failure. In patients with BD, severe atypia and higher age are associated with an increased risk of treatment failure after PDT.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
5-Aminolevulinic acid hydrochloride, BioReagent, suitable for cell culture, powder, ≥98%
Sigma-Aldrich
Fluorouracil, meets USP testing specifications
Sigma-Aldrich
5-Aminolevulinic acid hydrochloride, ≥98%
Sigma-Aldrich
5-Aminolevulinic acid hydrochloride, ≥97.0% (AT)
Sigma-Aldrich
5-Fluorouracil, Vetec, reagent grade, ≥99%
Sigma-Aldrich
Imiquimod, ≥98% (HPLC), solid
Sigma-Aldrich
5-Fluorouracil, ≥99% (HPLC), powder
Supelco
Fluorouracil, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Fluorouracil, United States Pharmacopeia (USP) Reference Standard
Fluorouracil, European Pharmacopoeia (EP) Reference Standard
Supelco
5-Fluorouracil, analytical standard
Sigma-Aldrich
3-(2-Pyridyl)-5,6-diphenyl-1,2,4-triazine, ≥99%